Ophthalmology

The investigational therapy has received orphan drug designation from the FDA for Stargardt disease as well as retinitis pigmentosa.

Kimmtrak is now the first approved therapy for unresectable or metastatic uveal melanoma.

The clinical trial of 4D-150 expects to enroll around 60 participants with wet AMD.

Both the Sirius and Celeste phase 2/3 trials are evaluating QR-421a.

Review top news and interview highlights from the week ending January 28, 2022.

Exciting new therapies are on the horizon for inherited retinal disease. We’ve compiled a quick snapshot of promising investigative therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

The ASCENT trial is kicking off while the ATMOSPHERE trial continues to screen patients with wet AMD.

ADVM-062 is designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients with BCM.

Many cell and gene therapy companies are initiating new programs and collaborations with the start of the new year.

Review some of our most-viewed coverage of advancements in cell therapies, including the latest study results and insights from experts in the field.

Vision loss was prevented in a mouse model of Fuchs endothelial corneal dystrophy.

Improved knowledge of the effects of mutations in the EYS gene may help inform new treatments.

Following GS030 optogenetic therapy, the first treated patient was able to locate and count objects on a table and could identify crosswalks in the street.

Current studies are using a polygenic risk score to evaluate the risk and clinical outcomes in primary open-angle glaucoma (POAG).

Findings from the phase 2 INFINITY trial identified dose-dependent safety outcomes of ADVM-022 in patients with diabetic macular edema.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.

The study is aiming to gain insight into glaucoma in African American populations.

The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.

Review top news and interview highlights from the week ending November 19, 2021.

The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.

The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the company’s ultimate goal of reversing aging.